DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lybrel (Levonorgestrel / Ethinyl Estradiol) - Summary

 
 



LYBREL SUMMARY

Important Points to Remember

Twenty-eight (28) yellow tablets each containing 90 mcg of levonorgestrel, a totally synthetic progestogen, and 20 mcg of ethinyl estradiol.

Lybrel is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.


See all Lybrel indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Lybrel (Levonorgestrel / Ethinyl Estradiol)

First scientific data for Lybrel presented at ASRM meeting
Source: The Doctors Lounge - Gynecology
Lybrel is an investigational combination low-dose oral contraceptive designed to be taken daily, 365 days a year.

Research reveals more than half of young women who have abortions were using contraception when they fell pregnant
Source: Abortion News From Medical News Today [2014.04.30]
Reproductive health charity Marie Stopes UK has launched the findings of the first research in the UK into the contraceptive use of women aged 16-24 having one or more abortions.

more news >>

Published Studies Related to Lybrel (Levonorgestrel / Ethinyl Estradiol)

Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. [2011.03]
Use of oral contraceptives (OC) that combine a progestogen with synthetic ethinyl estradiol (EE) is associated with increased risk of venous thromboembolism. NOMAC/E2 is a new monophasic OC that combines nomegestrol acetate (NOMAC), a highly selective progestogen, with 17beta-estradiol (E2)...

Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial. [2009.12]
BACKGROUND: This Phase 3, randomized, open-label, multicenter study conducted at 44 sites in Europe evaluated the safety and efficacy of a continuous, daily regimen of levonorgestrel (LNG) 90 mcg/ethinyl estradiol (EE) 20 mcg compared with a 21-day, cyclic LNG 100 mcg/EE 20 mcg regimen... CONCLUSIONS: Continuous LNG 90 mcg/EE 20 mcg was shown to be a safe and effective OC in this direct comparison to a cyclic OC. Suppression of menses and the potential for no bleeding requiring sanitary protection may be provided by this continuous, low-dose OC.

Cycle control with oral contraceptives containing 20 micrograms of ethinyl estradiol. A multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 micrograms/20 micrograms) and norethindrone/ethinyl estradiol (1000 micrograms/20 micrograms). [1999.03]
A randomized, open-label, multicenter study was undertaken to compare the effects of oral contraceptives (OC) containing 100 micrograms levonorgestrel (LNG)/20 micrograms ethinyl estradiol (EE) (Aless/Loette) and 1000 micrograms norethindrone acetate (NETA)/20 micrograms EE (Loestrin Fe 1/20) on menstrual cycle control over four cycles of use...

Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder. [2012.01]
BACKGROUND: The study was conducted to investigate continuous daily levonorgestrel 90 mcg/ethinyl estradiol 20 mcg (LNG/EE) on premenstrual dysphoric disorder (PMDD)... CONCLUSIONS: Continuous daily LNG 90 mcg/EE 20 mcg was well tolerated and may be useful for managing the physical, psychological and behavioral symptoms and loss of work productivity related to PMDD. Copyright (c) 2012 Elsevier Inc. All rights reserved.

Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen. [2009.09]
BACKGROUND: A continuous regimen of oral levonorgestrel (LNG) 90 mcg/ethinyl estradiol (EE) 20 mcg was evaluated for inhibition of ovulation, time to return to ovulation after stopping treatment and safety... CONCLUSIONS: The continuous LNG/EE regimen completely inhibited ovulation, with little evidence of follicular development and with rapid return of ovulatory capacity after stopping treatment.

more studies >>

Clinical Trials Related to Lybrel (Levonorgestrel / Ethinyl Estradiol)

Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects [Recruiting]
A crossover study to assess the effect of repeated doses of fostamatinib on the levels of oral contraceptive (Microgynon® 30) in the blood of healthy female subjects. The study will consist of a screening period of up to 35 days, followed by 2 treatment periods (28 days each) of an oral contraceptive (Microgynon® 30) in the absence and presence of fostamatinib. The study will also evaluate the safety and tolerability of fostamatinib in combination with an oral contraceptive

AZD6140 Oral Contraceptive Interaction Study [Recruiting]

A Study to Investigate the Potential Pharmacokinetic Interaction of Perampanel With Oral Contraceptives in Healthy Female Subjects [Recruiting]

Evaluation Of The Product Ciclo� 21 Pharmacodynamics (Levonorgestrel + Ethinyl Estradiol), Marketed By Uni�o Qu�mica Farmac�utica Nacional S / A, Compared To Nordette� Product To The Lab Wyeth Pharmaceutical Industries Ltd. [Not yet recruiting]
Assessment of the pharmacodynamic profile of the drug Ciclo 21 ®, marketed by União Química Farmacêutica Nacional S / A, compared to the drug Nordette ® Laboratory Wyeth Pharmaceutical Ltda. Through the modulation of hormonal response (inhibition of the pituitary) evidenced by measurement serum LH and FSH for 28 days, as well as by the absence of follicle formation demonstrated by transvaginal ultrasound examinations

Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne� or Placebo. [Recruiting]

more trials >>

Reports of Suspected Lybrel (Levonorgestrel / Ethinyl Estradiol) Side Effects

Metrorrhagia (6)Weight Increased (3)Menorrhagia (3)Dizziness (2)Increased Appetite (1)Appetite Disorder (1)Vaginal Haemorrhage (1)Menstruation Irregular (1)Androgen Deficiency (1)Oestrogen Deficiency (1)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 2 ratings/reviews, Lybrel has an overall score of 4. The effectiveness score is 5 and the side effect score is 7. The scores are on ten point scale: 10 - best, 1 - worst.
 

Lybrel review by 36 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   no more monthly periods
Dosage & duration:   1 pill per day taken every day for the period of since Nov. 2007
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   no more monthly periods
Side effects:   slight spotting for more than 7 days each cycle
Comments:   Since Nov 2007 I have been taking Lybrel to avoid my period. According to the manufacturer it is normal to have spotting for the first 6-12 month. I had many days of spotting until this July- so for 8 month. Since this August I had no more bleeding.

 

Lybrel review by 18 year old female patient

  Rating
Overall rating:  
Effectiveness:   Ineffective
Side effects:   Moderate Side Effects
  
Treatment Info
Condition / reason:   no more period
Dosage & duration:   normal dose (dosage frequency: everydat) for the period of 9 months
Other conditions:   non-stop bleeding for 9 months no sex drive rapid weight loss
Other drugs taken:   none
  
Reported Results
Benefits:   i couldn't get pregnant
Side effects:   * mild nausea, vomiting, bloating, stomach cramps; * breast pain, tenderness, or swelling; * freckles or darkening of facial skin; * increased hair growth, loss of scalp hair; * changes in weight or appetite; * problems with contact lenses; * vaginal itching or discharge; * changes in your menstrual periods, decreased sex drive; or * headache, nervousness, dizziness, tired feeling.
Comments:   take a pill everday peferablly the same time

See all Lybrel reviews / ratings >>

Page last updated: 2014-04-30

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014